AbbVie (ABBV) Stock Inflation-Adjusted

AbbVie Inc. (ABBV) is a global biopharmaceutical company focused on developing innovative advanced therapies for complex and critical conditions across immunology, oncology, neuroscience, and other specialty areas.

Analyzing a stock's price history alone can mask its true performance in terms of purchasing power. To evaluate AbbVie's genuine investment value, we need to consider inflation's effects. This page presents AbbVie's historical stock prices adjusted using the US Consumer Price Index, revealing the impact of inflation on its value.

Nominal prices are adjusted for stock splits and assume reinvestment of any dividends to reflect total return. Inflation-adjusted prices use December 2025 as the baseline (latest available CPI).

The current value of AbbVie stock is 218.67 (as of the close of Jan 28, 2026), 9.16% lower than the all-time high of 240.72 (Oct 1, 2025).

Since January 2, 2013, the inflation-adjusted total return for the stock has been 644.39%, which is equivalent to an annual growth rate of 16.6%.

In nominal values, the total return since this date has been 947.52%, or an annualized rate of 19.69%.

Inflation-Adjusted Values by Month

This data presents AbbVie's end-of-month closing levels over time. Inflation-adjusted figures show what past levels would be worth using roughly today's purchasing power (based on the latest CPI data). The latest entry in the table will have equal nominal and adjusted values until the next CPI figures are released.

Date	Inflation-Adjusted	Nominal value
Jan 2026	218.67	218.67
Dec 2025	226.68	226.68
Nov 2025	225.85	225.9
Oct 2025	216.31	216.31
Sep 2025	227.55	228.07
Aug 2025	207.3	207.25
Jul 2025	186.77	186.19
Jun 2025	182.13	181.29
May 2025	183.23	181.77
Apr 2025	192.48	190.55
Mar 2025	205.78	203.08
Feb 2025	205.76	202.6
Jan 2025	181.83	178.25
Dec 2024	175.21	170.64
Nov 2024	180.43	175.66
Oct 2024	200.98	195.77
Sep 2024	193.37	188.15
Aug 2024	192.53	187.03
Jul 2024	181.9	176.56
Jun 2024	167.03	161.94
May 2024	157.07	152.23
Apr 2024	158.7	153.56
Mar 2024	176.75	170.35
Feb 2024	171.98	164.69
Jan 2024	161.59	153.79
Dec 2023	151.72	143.61
Nov 2023	139.26	131.96
Oct 2023	137.8	130.83
Sep 2023	144.01	136.78
Aug 2023	142.33	134.85
Jul 2023	145.5	137.26
Jun 2023	129.88	122.29
May 2023	133.43	125.22
Apr 2023	146.52	137.17
Mar 2023	153.9	143.35
Feb 2023	149.11	138.43
Jan 2023	143.95	132.9
Dec 2022	157.23	144.01
Nov 2022	156.33	143.62
Oct 2022	141.85	130.45
Sep 2022	129.27	118.4
Aug 2022	129.79	118.62
Jul 2022	138.47	126.6
Jun 2022	146.41	133.88
May 2022	142.81	128.82
Apr 2022	143.91	128.39
Mar 2022	158.38	140.52
Feb 2022	146.3	128.09
Jan 2022	136.76	118.65
Dec 2021	135.03	116.17
Nov 2021	115.31	98.91
Oct 2021	115.27	98.38
Sep 2021	108.04	91.45
Aug 2021	121.3	102.4
Jul 2021	117.04	98.6
Jun 2021	112.66	94.46
May 2021	114.27	94.93
Apr 2021	113.46	93.5
Mar 2021	109.71	89.67
Feb 2021	109.99	89.28
Jan 2021	105.2	84.92
Dec 2020	109.2	87.77
Nov 2020	106.68	85.67
Oct 2020	86.75	69.71
Sep 2020	88.15	70.8
Aug 2020	96.51	77.41
Jul 2020	95.95	76.72
Jun 2020	98.57	78.41
May 2020	93.54	74.01
Apr 2020	82.98	65.65
Mar 2020	75.29	59.97
Feb 2020	84.51	67.46
Jan 2020	80.11	63.77
Dec 2019	86.73	68.77
Nov 2019	85.85	68.14
Oct 2019	77.81	61.79
Sep 2019	73.18	57.98
Aug 2019	63.58	50.34
Jul 2019	64.43	51.01
Jun 2019	69.41	54.86
May 2019	73.23	57.87
Apr 2019	75.95	59.89
Mar 2019	76.5	60.01
Feb 2019	75.65	59.01
Jan 2019	76.97	59.79
Dec 2018	87.49	67.83
Nov 2018	89.18	69.36
Oct 2018	73.4	57.28
Sep 2018	88.39	68.86
Aug 2018	89.81	69.88
Jul 2018	86.34	67.15
Jun 2018	85.88	66.78
May 2018	91.85	71.31
Apr 2018	90.01	69.59
Mar 2018	87.69	67.53
Feb 2018	107.55	82.64
Jan 2018	104.67	80.06
Dec 2017	90.05	68.51
Nov 2017	90.2	68.66
Oct 2017	83.99	63.93
Sep 2017	82.08	62.51
Aug 2017	69.92	52.98
Jul 2017	65.11	49.18
Jun 2017	66.89	50.56
May 2017	60.96	46.04
Apr 2017	60.94	45.98
Mar 2017	59.8	44.99
Feb 2017	56.8	42.7
Jan 2017	56.31	42.2
Dec 2016	57.46	42.81
Nov 2016	55.81	41.57
Oct 2016	51.12	38.14
Sep 2016	57.35	42.73
Aug 2016	58.43	43.43
Jul 2016	60.43	44.87
Jun 2016	55.91	41.58
May 2016	57.01	42.27
Apr 2016	55.49	40.97
Mar 2016	51.71	38
Feb 2016	49.66	36.33
Jan 2016	49.96	36.53
Dec 2015	53.44	39.01
Nov 2015	52.28	38.29
Oct 2015	53.43	39.21
Sep 2015	48.35	35.5
Aug 2015	55.37	40.72
Jul 2015	62.03	45.68
Jun 2015	59.1	43.52
May 2015	58.78	43.13
Apr 2015	57.36	41.88
Mar 2015	51.61	37.61
Feb 2015	53.66	38.87
Jan 2015	53.76	38.77
Dec 2014	57.59	41.73
Nov 2014	60.55	44.13
Oct 2014	55.23	40.47
Sep 2014	49.78	36.56
Aug 2014	47.67	34.99
Jul 2014	45.06	33.13
Jun 2014	48.21	35.46
May 2014	46.5	34.13
Apr 2014	44.73	32.72
Mar 2014	43.9	32.01
Feb 2014	43.76	31.7
Jan 2014	42.47	30.66
Dec 2013	45.37	32.63
Nov 2013	41.62	29.94
Oct 2013	41.54	29.94
Sep 2013	37.91	27.39
Aug 2013	36.16	26.1
Jul 2013	38.64	27.85
Jun 2013	34.82	25.09
May 2013	36.04	25.91
Apr 2013	38.95	27.95
Mar 2013	34.14	24.52
Feb 2013	30.99	22.2
Jan 2013	31.05	22.06

Returns from Investing in AbbVie stock

How much did an investment in AbbVie really grow each year after accounting for inflation? The following chart contains the inflation-adjusted real annual percentage returns.

Detailed Annual Returns (Adjusted vs. Nominal)

The table below shows the returns for AbbVie stock by year, both inflation-adjusted and nominal. You can sort any column by clicking on the header.

Observe how inflation erodes nominal gains, sometimes resulting in a negative real return even when the stock price nominally increased, as in 2019.

Year	Inflation-Adjusted Return	Nominal Return
2024	15.49%	18.82%
2023	-3.51%	-0.27%
2022	16.45%	23.96%
2021	23.65%	32.35%
2020	25.91%	27.63%
2019	-0.87%	1.39%
2018	-2.85%	-0.99%
2017	56.72%	60.02%
2016	7.52%	9.75%
2015	-7.2%	-6.53%
2014	26.93%	27.89%

Abbvie Stock: Average Annualized Returns

Annualized returns show the average rate of growth per year, making it easier to compare performance across different time periods. While nominal returns indicate the headline growth, adjusting for inflation reveals the actual change in purchasing power.

This table presents both nominal and inflation-adjusted average annual returns for AbbVie over various trailing periods ending December 31, 2025, offering a clearer view of long-term, real investment performance.

Period	Avg. Annual Return (Inflation-Adjusted)	Avg. Annual Return (Nominal)
Last 1 year	29.38%	32.84%
Last 3 years	12.97%	16.33%
Last 5 years	15.73%	20.9%
Last 10 years	15.55%	19.24%

Real Returns of Investing in the AbbVie

The chart and table below show the nominal and inflation-adjusted value of a hypothetical $100 investment over various long-term historical periods, ending in September 2025.

The inflation-adjusted line, in green, represents the real increase in purchasing power for the initial investment. Observe the gap between both lines, which illustrates the cumulative effect of inflation over time.

Even over just five years, inflation takes a noticeable bite out of investments. Investing $100 in the AbbVie five years ago yielded an 155.47% nominal gain, but the real return (the actual increase in buying power) was 106.87%.

As investment periods get longer, the difference between reported nominal returns and the inflation-adjusted gains usually becomes much greater due to the compounding effect of inflation over time.

Investment Period	What $100 Grew To (Nominal)	Total Nominal Return (%)	Total Inflation-Adjusted Return (%)
Last 5 years Feb 2021 - Sep 2025	$255.47	155.47%	106.87%
Last 10 years Feb 2016 - Sep 2025	$627.74	527.74%	358.26%

Inflation Impact on AbbVie

AbbVie experiences moderate exposure to inflation throughout its business operations.

Research & Development: As a pharmaceutical company, AbbVie invests heavily in R&D. Inflation can increase the costs of clinical trials, research equipment, and scientific talent, potentially affecting the pace and scope of innovation.
Manufacturing & Supply Chain: Rising costs for raw materials, energy, and transportation can increase production expenses for AbbVie's drug portfolio, including its flagship immunology drug Humira and newer offerings like Skyrizi and Rinvoq.
Fixed Asset Investment: Inflation increases the costs of building and maintaining specialized manufacturing facilities and laboratory infrastructure, requiring higher capital expenditures.
Global Operations: With business across multiple countries, AbbVie faces varying inflation rates and currency fluctuations that can impact both costs and revenue when consolidated into USD financial reporting.

AbbVie mitigates these inflationary pressures through several approaches. The company's strong pricing power in specialty pharmaceuticals allows it to adjust prices of patented medications in line with or above inflation in many markets, though this ability varies by country due to different healthcare systems and regulations.

Additionally, AbbVie employs strategic long-term contracts with suppliers and manufacturers to stabilize input costs and implements operational efficiency initiatives to offset rising expenses. The company's robust cash flow enables it to continue critical investments despite inflationary environments, while its diverse product portfolio provides revenue stability across economic cycles.

About AbbVie

AbbVie Inc. is a research-driven biopharmaceutical company that was formed in 2013 when it was spun off from Abbott Laboratories.

The company develops and markets advanced therapies that address some of the world's most complex and serious diseases. AbbVie's portfolio spans multiple therapeutic areas, with particular strength in immunology and oncology. Its flagship drug Humira has been one of the world's top-selling pharmaceuticals, though the company has worked to diversify its revenue streams as Humira faces biosimilar competition.

Headquartered in North Chicago, Illinois, AbbVie employs thousands of scientists, researchers, and other professionals worldwide and maintains a consistent focus on innovation through significant R&D investment. AbbVie stock is a component of major indices including the S&P 500.

Last Close Jan 28, 2026	218.67
Highest Oct 1, 2025	240.72
Highest, Inflation-Adjusted Oct 1, 2025	240.72
Annualized return Since Jan 2, 2013	19.69%
Annualized return, Inflation-Adjusted Since Jan 2, 2013	16.6%